TEIKOKU CHEMICAL AND EISAI CONCLUDE AGREEMENT FOR THE DEVELOPMENT AND MARKETING OF NEW H. PYLORI ERADICATION TREATMENT
(August 23, 2000) - Nagase & Co., Ltd. of Tokyo and Osaka, (President: Hiroshi Nagase) Group company, Teikoku Chemical Industries Co., Ltd. of Osaka (President: Hiroshi Nagase) and Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced the conclusion of an agreement for the development and marketing of Teikoku Chemical's newly synthesized H. pylori eradication compound (Development Code: TKS1044). Under the terms of the agreement, Eisai will have exclusive worldwide rights for the development and marketing of the compound.
TKS1044 is a newly synthesized compound that has a mechanism effective in the eradication of H. pylori. In non-clinical studies to date, TKS1044 has indicated it is highly selective in vitro in the eradication of H. pylori in as well as effective against clarithromycin, metronidazole, and amoxicillin resistant bacteria strains. The compound has been shown to be chemically stable in vitro in the gastric acids of the stomach.
H. pylori is a bacteria that resides in the stomach and has been shown to be a cause of the development of duodenal and gastric ulcers. After the eradication of H. pylori, the recurrence rate of ulcers is low. The current worldwide treatment for the eradication of H. pylori involves the utilization of a proton pump inhibitor in combination with antibiotics.